Shares of Smith & Nephew plc (LON:SN – Get Free Report) have earned a consensus recommendation of “Hold” from the nine analysts that are covering the company, MarketBeat reports. Six equities research analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is GBX 1,293.33.
A number of research analysts have recently commented on SN shares. Shore Capital Group reiterated a “buy” rating and issued a GBX 1,000 price target on shares of Smith & Nephew in a research note on Tuesday, July 21st. Berenberg Bank reduced their price objective on Smith & Nephew from GBX 1,300 to GBX 1,250 and set a “hold” rating on the stock in a research report on Friday, August 14th. Royal Bank Of Canada lowered their target price on Smith & Nephew from GBX 1,350 to GBX 1,250 and set a “sector perform” rating for the company in a report on Thursday, August 6th. Jefferies Financial Group reiterated a “buy” rating and issued a GBX 1,500 target price on shares of Smith & Nephew in a research report on Friday, September 4th. Finally, JPMorgan Chase & Co. cut their price target on Smith & Nephew from GBX 1,438 to GBX 1,290 and set a “neutral” rating on the stock in a research note on Thursday, August 6th.
Read Our Latest Research Report on SN
Smith & Nephew Price Performance
Smith & Nephew Company Profile
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.
Recommended Stories
- Five stocks we like better than Smith & Nephew
- NVIDIA Just Named AI’s Next Bottleneck—And These 3 Stocks Sit Right In It
- Gold Has Gone Sideways, But These 3 Stocks Haven’t
- The AI Bottleneck Is Not Chips Anymore and 3 Pipeline Stocks Are Cashing In
- These 3 Stocks Under $20 Have Wall Street Looking Past the Share Price
Receive News & Ratings for Smith & Nephew Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew and related companies with MarketBeat.com's FREE daily email newsletter.
